Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Q-linea AB's retained earnings for the quarter that ended in Mar. 2026 was kr-1,731.12 Mil.
Q-linea AB's quarterly retained earnings
declined
from Sep. 2025 (kr-1,652.30 Mil) to Dec. 2025 (kr-1,690.00 Mil) and
declined
from Dec. 2025 (kr-1,690.00 Mil) to Mar. 2026 (kr-1,731.12 Mil).
Q-linea AB's annual retained earnings
declined
from Dec. 2023 (kr-1,298.84 Mil) to Dec. 2024 (kr-1,517.41 Mil) and
declined
from Dec. 2024 (kr-1,517.41 Mil) to Dec. 2025 (kr-1,690.00 Mil).
Q-linea AB (CHIX:QLINEs) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Q-linea AB Retained Earnings Historical Data
* Premium members only.
The historical data trend for Q-linea AB's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
What does a Retained Earnings of kr-1,731.12 Mil mean?
Q-linea AB (CHIX:QLINES) has a Retained Earnings of kr-1,731.12 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Q-linea AB and its competitors.
Is Q-linea AB's Retained Earnings too high?
Q-linea AB's current Retained Earnings is kr-1,731.12 Mil. Overall, Q-linea AB has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Retained Earnings compare to ABT and SYK?
Q-linea AB's Retained Earnings of kr-1,731.12 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Q-linea AB and its competitors. Q-linea AB's current Retained Earnings is kr-1,731.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current Retained Earnings of kr-1,731.12 Mil. The stock's GF Value™ is kr1,921.76, compared to a current price of kr1,610.00 — trading 16.2% below its estimated fair value. The current Retained Earnings is kr-1,731.12 Mil. Q-linea AB's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current Retained Earnings is kr-1,731.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 16.2% below its estimated GF Value™ of kr1,921.76.
Key valuation signals for CHIX:QLINES:
Retained Earnings: kr-1,731.12 Mil
GF Value™: kr1,921.76 vs. price of kr1,610.00 (16.2% below fair value)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
67GF Score
Get the complete analysis for CHIX:QLINES
Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 
